Lower body mass index is associated with the achievement of target LDL in patients using PCSK9 inhibitors in Taiwan

Table 2 The lipid profile and other biochemical data at baseline

Baseline	LDL target non-achiever	LDL target achiever	Total	P value
Baseline	N = 91	N = 120	N = 211	P value
Cholesterol (mg/dL)	206.0 (170.0, 248.0)	216.0 (179.5, 263.0)	212.0 (175.0, 252.0)	0.187
LDL-C (mg/dL)	135.0 (108.0, 172.0)	147.0 (110.0, 183.5)	143.0 (108.0, 174.0)	0.108
HDL-C (mg/dL)	40.0 (35.9, 47.0)	41.0 (36.3, 52.1)	41.0 (36.0, 50.0)	0.264
Triglyceride (mg/dL)	130.5 (98.0, 178.5)	150.0 (103.0, 213.0)	141.5 (99.0, 205.0)	0.141
Fasting sugar (mg/dL)	103.0 (94.0, 121.0)	106.5 (92.0, 124.0)	105.0 (94.0, 123.0)	0.666
HbA1C	6.0 (5.7, 6.8)	5.9 (5.5, 6.5)	6.0 (5.6, 6.7)	0.300
AST (U/L)	24.0 (20.0, 37.0)	27.0 (20.0, 35.0)	25.0 (20.0, 35.0)	0.842
ALT (U/L)	24.5 (17.0, 45.0)	29.0 (20.5, 40.0)	26.5 (19.0, 41.0)	0.326
Creatinine (mg/dL)	1.0 (0.8,1.1)	0.9 (0.8, 1.1)	0.9 (0.8, 1.1)	0.655

AST: aspartate aminotransferase; ALT: alanine aminotransferase; HDL-C: high-density lipoprotein cholesterol; HbA1C: glycated hemoglobin; LDL-C: low-density lipoprotein cholesterol

ISSN: 2047-783X